Jade Biosciences, Inc. (JBIO) Form 424B5 — Jun 4, 2026
Jade Biosciences, Inc. (JBIO) has priced a $150 million follow-on public offering of 10 million shares of common stock at $15.00 per share, with an additional 1.5 million shares available via the underwriters' greenshoe option. The offering is being led by Jefferies, TD Cowen, and UBS, with net proceeds to the company estimated at approximately $140.3 million after deducting underwriting discounts and expenses. The offering comes on the heels of positive interim Phase 1 data for JADE101, the company's lead candidate for IgA nephropathy, which showed approximately 70% reduction in IgA levels and a favorable safety profile in healthy volunteers.
Key figures
- Greenshoe
- 1500000
- Net Proceeds
- 140300000
- Gross Proceeds
- 150000000
- Offering Price
- 15
- Shares Offered
- 10000000
- Shares Outstanding
- 49345967
- Dilution Per Share
- 7.64
- Atm Capacity Remaining
- 200000000
- Net Tangible Book Value Per Share
- 6
- Adjusted Net Tangible Book Value Per Share
- 7.36
Price after filing
Close on the filing date to close N calendar days later (from $17.74). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.